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Background: It is well recognized that the presence of positive surgical margins (PSM) after radical prostatectomy
(RP) adversely affects cancer specific outcomes and recent evidence from randomized trials supports the use of
adjuvant radiotherapy in these cases. However, not all of the patients with PSM develop disease recurrence and
the policy of adjuvant radiation could result in considerable over-treatment. We investigated the ability of early
postoperative prostate specific antigen (PSA) and PSA decline rates to stratify the risk of disease progression
during the first weeks after the surgery thereby allowing adequate time for planning eventual adjuvant therapy.
Methods: We studied 116 consecutive patients with the finding of PSM after RP for localized prostate cancer
between 2001 and 2012. No patients were treated with radiation or hormonal therapy. An intensive postoperative
PSA monitoring using ultrasensitive assay started first at day 14 after the surgery, then at day 30, 60, 90 and 180,
and subsequently in 3 monthly intervals. Biochemical recurrence (BCR) presented the failure of surgical treatment
and it was defined as PSA ≥0.2 ng/ml. The ability of PSA decline parameters to predict BCR was assessed using
Cox regression model and area under the curve (AUC) calculation.
Results: Overall 55 (47%) patients experienced BCR during median follow-up of 31.4 months (range 6–69).
Preoperative PSA, pathologic Gleason sum and pathologic grade failed to reveal any association with
observation of BCR. Postoperative PSA levels achieved significant predictive accuracy already on day 30
(AUC 0.74). PSA >0.073 ng/ml at day 30 increased significantly the risk of BCR (HR 4.35, p < 0.001). Predictive
accuracy was significantly exceeded on day 60 (AUC 0.84; p < 0.001), while further enhancements on day 90
(AUC 0.84) and 180 (AUC 0.91) were not significant.
Conclusions: The level of ultrasensitive PSA yields valuable information about the prostatectomy outcome already
at the first month after the surgery and should aid risk stratification in patients with PSM. Patients not likely to
experience subsequent disease progression may be spared the toxicity of immediate adjuvant radiotherapy.
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Although radical prostatectomy provides excellent con-
trol for localized prostate cancer, pathologic examination
of approximately one-third of specimens will reveal posi-
tive surgical margins (PSM) [1,2]. Numerous studies re-
port that the presence of PSM adversely affects cancer
specific outcomes and considerably increases the risk of* Correspondence: stepan.vesely@fnmotol.cz
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unless otherwise stated.biochemical recurrence (BCR) [3]. However, the optimum
management of patients with PSM remains controversial.
Evidence from randomized trials suggests that imme-
diate radiotherapy after the surgery, rather than watchful
waiting, is more appropriate for the patient with patho-
logically advanced disease because it can improve cancer-
specific and overall survival [4-6]. Despite the fact that the
most contemporary guidelines do not uniformly recom-
mend adjuvant therapy for patients with adverse patho-
logic characteristics at radical prostatectomy, it has beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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were significantly more likely to receive immediate adju-
vant treatment [7].
But not all of the patients with PSM develop BCR and
the policy of adjuvant radiotherapy could result in con-
siderable over-treatment. Therefore correct identification
of those patients most likely to benefit from adjuvant
management is of paramount importance. However, at-
tempts to improve early staging after the surgery already
hint at several difficulties. The ability of imaging modal-
ities remains limited [8]. The impact of PSM-associated
variables (location, focality, length and Gleason score at
the margin) on clinical decision making was not clearly
established yet [2]. Even routine use of frozen section on
all cases has not fulfilled its expectation to provide ef-
fective control of surgical margin status [9,10].
Postoperative PSA measurements are generally per-
formed 3 months after the surgery, although a significant
decline in PSA may be detectable much earlier. Results
from several studies indicate that intensive monitoring
of PSA changes early after radical prostatectomy may
provide clinically useful information, which facilitates
identification of surgical failure [11-14]. Moreover, re-
cently introduced ultrasensitive PSA detection techniques
are offering a new insight into the changes in serum PSA
at very low concentration. It has been demonstrated that
after a properly performed radical prostatectomy, measur-
able PSA is most likely attributed to the presence of active
prostate cancer cells rather than to retained benign pros-
tatic tissue [15,16]. It is therefore conceivable, that real
candidates for immediate adjuvant therapy, who have ac-
tive prostate cancer cells remaining in the body after the
surgery, should present with higher postoperative serum
PSA in a comparison to individuals with incorrect diagno-
sis of PSM.
This hypothesis prompted us to evaluate the ability of
early postoperative ultrasensitive PSA levels to reduce
the overtreatment rate by further stratification of poten-
tial candidates for immediate adjuvant radiotherapy.
Methods
The study has received ethical approval by institutional
review board of the University Hospital Motol (approval
reference: EK-377/13). Data from 871 consecutive patients
who underwent open or laparoscopic radical prostatec-
tomy for clinically localized prostate cancer between May
2001 and March 2012 at our institution were reviewed.
Pathological evaluation of prostate cancer surgical speci-
men revealed PSM in 183 patients (21.0%). Of these 183
patients, 63 (34.4%) received adjuvant treatment in terms
of radiation or hormonal manipulation and these patients
were excluded from the analysis. In order to provide the
most accurate calculation of postoperative PSA dynamic, pa-
tients treated with neo-adjuvant hormonal and/or radiationtherapy prior to the surgery were excluded from the
study as well (n = 2). Additionally, since pelvic lymphade-
nectomy was not routinely performed in all of the patients,
nodal involvement was not included in the statistical
analysis and these patients (n = 2) were excluded from
the study. This resulted in a final cohort of 116 patients
available for statistical evaluation. Statistical comparison
of clinico-pathological characteristics (PSA at diagnosis,
Gleason grade, T stage) of patients with PSM excluded
from the study did not differ significantly from the stud-
ied cohort (Chi-square test, Mann–Whitney test).
A positive surgical margin was defined as the presence
of tumor at the inked surface of the resected specimen.
Tumors were staged according to the 2002 TNM staging
system. Extraprostatic extension was defined as the ex-
tension of the tumor beyond the confines of the gland
into the periprostatic soft tissue. Prostate cancer Gleason
grading was performed by a dedicated genitourinary path-
ologist. PSA determinations were carried out postopera-
tively on days 14, 30, 60, 90, 180 and at three monthly
intervals thereafter. All the PSA tests were performed in
a single hospital laboratory under standardized settings
using the Immulite third-generation PSA assay (Diag-
nostic Products Corp, Los Angeles, California; lower de-
tection limit 0.003 ng/ml). Biochemical recurrence was
defined as a single post-nadir PSA level of 0.2 ng/ml or
greater.
Statistical analysis was performed with the SAS statis-
tical software program JMP 6 (SAS Institute, Cary, NC,
USA). Mann–Whitney test and Chi-square test were
used to compare several variables between groups of pa-
tients. The cut-off values of serum PSA that best pre-
dicted the biochemical progression were determined by
using the Partition platform of the software. Patients
were censored at the time of their last tumor-free clinical
follow-up appointment. Survival analysis was performed
using the Cox proportional hazard model. Pearson's
correlation coefficient was used to examine the relation-
ship between continuous variables. The receiver operat-
ing characteristic curve (ROC) and area under the curve
(AUC) were determined to describe the accuracy in pre-
dicting BCR post-surgically. The significance of the dif-
ference in predictive accuracy between areas under
particular ROC curves was assessed with the method of
DeLong et al. [17]. A P value less than or equal to 0.01
was considered statistically significant.
Results
For a total of 116 patients with the finding of PSM after
radical prostatectomy, median follow-up was 31.4 months
(range 6–69). Of this cohort 55 (47%) patients experienced
BCR. Median patient age at operation was 64 years (range
49–76). Median duration of time to BCR was 12 months
(range 2–66). Median preoperative value of PSA was
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stage the distribution of the patients was as follows: T1c
(n = 64), T2a (n = 28), T2b (14) and T2c (n = 10). The fre-
quency of BCR did not differ significantly (p = 0.08) be-
tween clinical T categories: T1c (38%), T2a (54%), T2b
(71%) and T2c (60%). Pathological examination of the spe-
cies revealed Gleason score ≥7 in 59 (51%) patients, extra-
prostatic extension in 51 (43.9%) patients and seminal
vesicle invasion in 11 (9.48%) patients. Except at day 14,
postoperative PSA levels were identified to be significantly
associated with observation of BCR (P < 0.001), while
other conventional clinicopathologic variables failed to re-
veal significance (Table 1). Of all PSM locations, 15 (13%)
were apical, 20 (17%) at the bladder neck and 81 (70%) at
the posterolateral site. A total of 46 patients (40%) had
PSM ≤ 1 mm. Neither the location (p = 0.216) nor the ex-
tent of PSM (p = 0.405) had any significant impact on the
frequency of BCR. There were 36 men with the combin-
ation of all the adverse pathologic features (PSM and
Gleason score ≥7 and extraprostatic extension) and these
patients did not experienced significantly different rate of
BCR (55%) in the comparison with the rest of the cohort
(44%, P = 0.293). Calculated cut-off values for particular
PSA measurement on day 14, 30, 60, 90 and 180 were
0.707 ng/ml, 0.073 ng/ml, 0.041 ng/ml, 0.012 ng/ml and
0.021 ng/ml, respectively.
The ability of postoperative PSA values to predict
surgical failure was tested in the Cox proportional
model. Apart from non-significant result for PSA at
day 14, the risk of surgical failure predicted by PSA was
increasing gradually with the time distance from the
surgery (Table 2). Correlation between the preoperative
PSA and postoperative ultrasensitive PSA was signifi-
cant only on day 14 (r = 0.64, P < 0.001) and day 30 (r = 0.22,
P < 0.01), while at day 60 (r = 0.05, P = 0.61), day 90Table 1 Differences in potential predictive parameters accord
Parameters BCR
n 55
Pre-operative PSA (ng/ml, range) 9.20 (2.85-38.20)
Pathologic Gleason sum ≥ 7 27 (49.1%)
Pathologic extraprostatic extension 25 (45.5%)
Seminal vesicle invasion 8 (14.5%)
PSA – day 14 (ng/ml, range) 0.298 (0.071-1.940)
PSA – day 30 (ng/ml, range) 0.085 (0.008-0.747)
PSA – day 60 (ng/ml, range) 0.041 (0.003-0.882)
PSA – day 90 (ng/ml, range) 0.042 (0.003-1.010)
PSA – day 180 (ng/ml, range) 0.013 (0.015-1.167)
PSA nadir (ng/ml, range) 0.022 (0.003-0.137)
Time to PSA nadir (months, range) 2 (0.5-3)
BCR, biochemical recurrence; PSA, prostate specific antigen;
Data presented as n (%) or median (range).(r = 0.013, P = 0.89) and day 180 (r = 0.16, P = 0.10) no
significance was found.
Calculated AUC values for PSA cut-offs on day 14, 30,
60, 90 and 180 were 0.58 (95% CI: 0.45-0.69; P = 0.259),
0.74 (95% CI: 0.64-0.82; P < 0.001), 0.84 (95% CI: 0.75-
0.91; P < 0.001), 0.84 (95% CI: 0.75-0.90; P < 0.001) and 0.91
(95% CI: 0.84-0.96; P < 0.001), respectively. ROC curves
and calculated AUC values are depicted in Figure 1.
Positive/negative predictive values for particular PSA
cut-offs on day 14, 30, 60, 90 and 180 were 73%/63%,
81%/72%, 96%/67%, 73%/90% and 83%/87%. Calculated
PSA decline adjusted for preoperative baseline (PSA on
particular measurement day/preoperative PSA) did not
improve the prediction of BCR. Calculated AUC values
for PSA decline cut-offs on day 14, 30, 60, 90 and 180
were 0.52 (95% CI: 0.40-0.64; P = 0.745), 0.72 (95% CI:
0.62-0.80; P < 0.001), 0.82 (95% CI: 0.73-0.89; P < 0.001),
0.82 (95% CI: 0.73-0.88; P < 0.001) and 0.88 (95% CI:
0.81-0.94; P < 0.001), respectively.
Applying the PSA cut-off at day 30 as the indicator for
adjuvant radiotherapy would result in the decrease of
overtreatment from 61 patients (53%) to 8 patients (19%).
From 21 patients (28%) who would stay undertreated, 18
patients would reveal the PSA progression at day 90 while
only 2 patients would stay undertreated to late appearance
of BCR after 39 and 48 months. Only 1 out of 16 patients
who presented at day 30 with PSA ≤0.01 ng/ml developed
BCR during the follow-up.
Discussion
The removal of the entire prostate gland is a primary
goal of radical prostatectomy. A positive surgical margin
is defined as the presence of tumor at the inked surface
of the resected specimen and as such implies inadequate














Table 2 Cox regression analyses of PSA cut-offs at
particular postoperative measurement day as a predictor
of BCR
Parameters Hazard ratio p value
PSA – day 14 (0.707 ng/ml) 2.60 (1.24-5.56) 0.133
PSA – day 30 (0.073 ng/ml) 4.35 (2.39-8.06) <0.001
PSA – day 60 (0.041 ng/ml) 9.59 (5.15-17.95) <0.001
PSA – day 90 (0.012 ng/ml) 12.34 (4.98-41.09) <0.001
PSA – day 180 (0.021 ng/ml) 12.85 (6.29-29.82) <0.001
BCR, biochemical recurrence; PSA, prostate specific antigen; PSM, positive
surgical margins.
Data presented as PSA-measurement day (cut-off value) and hazard ratio
(95% confidence interval).
Vesely et al. BMC Urology 2014, 14:79 Page 4 of 6
http://www.biomedcentral.com/1471-2490/14/79and the significant stage shift in newly diagnosed pros-
tate cancer in the last decade, PSM are still reported in
11–38% of patients who have undergone RP [1,2]. Com-
parable results were found in the present study, where
PSM was diagnosed in 21% of patients after radical
prostatectomy.
Although the true impact of a PSM remains controver-
sial, many authorities agree it presents a significant risk
of biochemical and subsequent clinical relapse. Authors
from Johns Hopkins Hospital reported 79% of men with
negative margins were progression-free over a 10 year
period compared with 55% of those with positiveFigure 1 Receiver operating characteristics (ROC) curves and calculate
postoperative measurement day, devised for predicting biochemicalmargins [18]. Others have demonstrated similar findings
[3,19]. However not every patient will suffer eventual
disease recurrence and the policy of adjuvant radiother-
apy could result in considerable over-treatment. In the
observation arms of large randomized trials where high-
risk patients were involved, up to 52% did not show a
BCR during the follow-up [20]. However, some results
of these trials are conflicting due to the differences in
the number and type of adverse pathologic characteris-
tics included [21]. It has been demonstrated that in daily
clinical practice, positive surgical margins present an in-
dependent predictor of secondary prostate cancer treat-
ment [7]. Therefore, in our study we based the analysis
only on a cohort of patients with the diagnosis of PSM and
we found out that potential adjuvant radiation would re-
sult in overtreatment in the majority of the patients (53%).
Several explanations may explain why a positive mar-
gin is not always associated with the recurrence of can-
cer. It has been proposed that ischemia and fibrosis as a
consequence of the surgery may destroy small areas of
residual carcinoma [22]. Possible disruption of additional
tissue covering cancer cells during all the handling of
the specimen by surgeons, nurses and pathologists may
result in inadvertent damage leading to the false impres-
sion of PSM. Finally the experience of the reading path-
ologist and the type of classification may influence thed area under the curve (AUC) values for PSA at particular
recurrence.
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the question remains how to reliably identify patients
with residual prostate cancer cells in the surgical bed
who would be the best candidates for immediate adju-
vant treatment.
The ability of imaging modalities in the staging
process of prostate cancer remains limited. Current im-
aging devices are not endowed with sufficient resolution
to detect extraprostatic extension, which is often micro-
scopic [8]. Several groups have highlighted potential prog-
nostic value of additional pathological factors such as the
location, extent and number of positive margins [19,23].
However, the subclassification of positive margins has not
been standardized and there is no general consensus in
the literature on how specific PSM-associated prognostic
variables influence BCR or assist in clinical decision-
making [2]. Intraoperative frozen section biopsy has been
recommended in radical prostatectomy. However, routine
use of frozen section on all cases to be “sure” of getting
negative margins has not fulfilled its dream [9,10]. A num-
ber of authors have described prognostic significance of
PSM after adjusting for other clinical and pathological var-
iables. The Johns Hopkins group demonstrated the effect
of Gleason grade on outcome in men with positive mar-
gins. They reported positive surgical margins had no
impact on 10 y probability of biochemical recurrence in
men with Gleason score less than 7 [24]. Conversely, in
our series of men with PSM, we have not noted any im-
pact of age, Gleason score and/or the extraprostatic ex-
tension of the prostate cancer on the frequency of BCR.
Ultrasensitive PSA assessed early after the operation
was the only variable predicting the disease progression.
With removal of all the prostate cancer tissue, the
serum PSA should rapidly decline to zero, or at least
very close to zero within 2 to 6 weeks following radical
prostatectomy. However, general recommendation ad-
vises to perform the first PSA check at 3 months after
the surgery, although a significant decline in PSA and
even the PSA nadir may be reached a few weeks prior to
this point [11]. These results prompted us to investigate
the PSA kinetics early after the surgery, starting with the
first measurement at day 14. Our data demonstrate that
PSA at day 14 is not offering valuable prognostic infor-
mation regarding the outcome of the surgery. However,
as time from surgery increased, the predictive power of
ultrasensitive PSA measurements increased. For example,
the calculated AUR for day 30 and day 60 were 74% and
84%, respectively. Serum PSA at early moments after the
surgery may be influenced by the clearance of PSA, which
was produced by the tissue of ablated prostate. This is
compatible with our finding that preoperative PSA corre-
lated only with postoperative PSA at day 14 and at day 30.
It has been shown that retained benign prostatic ele-
ments are an unlikely source of elevated PSA levels inmen who have undergone radical prostatectomy. In a
study of Godoy et al. only 0.3% out of 331 men with
low-risk prostate cancer had developed a measurable
PSA level after radical prostatectomy [16]. Odisho et al.
have reviewed 274 patients with benign glandular tissue
at the surgical margin after radical prostatectomy. They
concluded that this finding was not associated with
postoperative elevation of PSA [15]. Thus, it seems that
the only significant source of PSA after radical prosta-
tectomy may be retained malignant cells and PSA kinetics
early after the surgery are key to identification of patients
with prostate cancer who have received failed prior
therapy. In a series of Hong et al. there were 106
(27.6%) subjects who had a positive surgical margin
after radical prostatectomy. Among these men, 45 pa-
tients, who showed undetectable ultrasensitive PSA
nadir (PSA < 0.001 ng/ml) during the postoperative
follow-up, demonstrated a significantly higher rate of 3-
year biochemical recurrence-free survival compared
with 61 men who did not (94.1% vs 57.1%, P < 0.001). In
line with these results we observed that only 1 of 16 pa-
tients who reached PSA ≤0.01 ng/ml at the first month
after the surgery experienced BCR during the follow-up.
This study has several potential limitations. These in-
clude limitations inherent to any retrospective study.
There were no strict criteria for subjecting the patients
with PSM after radical prostatectomy to adjuvant ther-
apy during the whole study period. It may be argued that
by doing so some patients with PSM who received adju-
vant treatment were at high risk of the recurrence and
they were excluded from the analysis. However, the com-
parison of clinicopathological characteristics did not reveal
any significant difference between studied group of pa-
tients and those who underwent immediate secondary
therapy after the surgery. Another limitation of our study
was the relatively short mean follow-up of 31 months.
Several investigators have reported that most biochemical
recurrences are detected within the first 3 years after
radical prostatectomy [25]. Nevertheless, presented re-
sults should be analyzed with caution, as patients with
BCR do not necessarily share the same long-term cancer
outcomes. Our results will need re-evaluation as our
follow-up matures to yield meaningful data on cancer
specific survival, as the most relevant endpoint.Conclusions
The present study provides insights into the role ultra-
sensitive serum PSA measurements plays in determin-
ing who will develop BCR after radical prostatectomy
and, such as, be candidates for secondary treatment.
The kinetics of postoperative PSA decline may allow
better stratification of patients who would benefit from
immediate radiation therapy.
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